Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase III VANQUISH-1 study, ...

Researchers from Johns Hopkins University have developed an oral treatment that could soon be used to destroy cancer cells and even prevent the disease from forming in the human body.

Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy ...

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

As drug-resistant infections continue to rise, researchers are looking for new antimicrobial strategies that are both ...

Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsMatthew Duffy - Chief Business Officer & ...

Minnow Inhalerx hopes to be first to market with inhaled synthetic medical cannabis therapies for cancer pain and panic ...

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

Bentham Science’s new release, Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma – Ocular Hypertension, compiles rigorously tested experimental methods aimed at advancing ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...